Safety and tolerability of fingolimod 0.5 mg during the first 4 months of administration in patients with relapsing forms of multiple sclerosis. Results from the open-label, multicentre FIRST study

Benzer Materyaller

• Cardiac safety of fingolimod 0.5 mg during the first-dose observation in a 4-month, open-label, multicentre FIRST study in relapsing multiple sclerosis patients
  Yazar:: Gold, R, ve diğerleri
  Baskı/Yayın Bilgisi: (2012)
• Cardiac Safety of Fingolimod 0.5 mg during the First Dose Observation in 4-Month, Open-Label, Multi-Center FIRST Study in Patients with Relapsing MS
  Yazar:: Comi, G, ve diğerleri
  Baskı/Yayın Bilgisi: (2012)
• Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label study.
  Yazar:: Gold, R, ve diğerleri
  Baskı/Yayın Bilgisi: (2014)
• Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: A phase 3b, open-label study
  Yazar:: Gold, R, ve diğerleri
  Baskı/Yayın Bilgisi: (2014)
• Erratum to: Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label study.
  Yazar:: Gold, R, ve diğerleri
  Baskı/Yayın Bilgisi: (2014)